Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke

Translational Stroke Research

Volumn 3, Issue 1, 2012, Pages 154-163

  Belayev, Ludmila ^a   Eady, Tiffany N ^a   Khoutorova, Larissa ^a   Atkins, Kristal D ^a   Obenaus, Andre ^b   Cordoba, Marta ^c   Vaquero, Juan J ^c   Alvarez Builla, Julio ^c   Bazan, Nicolas G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

LAU 0901; Magnetic resonance imaging; Middle cerebral artery occlusion; Neuroprotection; PAF antagonist; Stroke

Indexed keywords

2,4,6 TRIMETHYL 1,4 DIHYDRO 3,5 PYRIDINEDICARBOXYLIC ACID 2 (3,4 DICHLOROPHENOXY)ETHYL BIS(MORPHOLINOMETHYL)METHYL ESTER; CD68 ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEHAVIOR CHANGE; BRAIN CELL; BRAIN CORTEX; BRAIN EDEMA; BRAIN INFARCTION SIZE; CELL INFILTRATION; CELL SURVIVAL; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG EFFICACY; HISTOPATHOLOGY; IMMUNOPATHOLOGY; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; STROKE; SUBCORTEX;

EID: 84857646856     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-011-0116-y     Document Type: Article

References (32)

1. Armstead WM, Ganguly K, Kiessling JW, Riley J, Chen XH, Smith DH, et al. Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA for treatment of CNS ischemic disorders. J Neurochem. 2010; 113: 303-12.
2. Bazan NG. Lipid signaling in neural plasticity, brain repair, and neuroprotection. Mol Neurobiol. 2005; 32: 89-103.
3. He J, Bazan HE. Synergistic effect of platelet-activating factor and tumor necrosis factor-alpha on corneal myofibroblast apoptosis. Invest Ophthalmol Vis Sci. 2006; 47: 883-91.
4. Cortina MS, Gordon WC, Lukiw WJ, Bazan NG. Oxidative stress-induced retinal damage up-regulates DNA polymerase gamma and 8-oxoguanine-DNA-glycosylase in photoreceptor synaptic mitochondria. Exp Eye Res. 2005; 81: 742-50.
5. Esquenazi S, He J, Bazan HE, Bazan NG. Prevention of experimental diffuse lamellar keratitis using a novel platelet-activating factor receptor antagonist. J Cataract Refract Surg. 2004; 30: 884-91.
6. Boetkjaer A, Boedker M, Cui JG, Zhao Y, Lukiw WJ. Synergism in the repression of COX-2- and TNFalpha-induction in platelet activating factor-stressed human neural cells. Neurosci Lett. 2007; 426: 59-63.
7. Belayev L, Marcheselli VL, Khoutorova L, Rodriguez de Turco EB, Busto R, Ginsberg MD, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke. 2005; 36: 118-23.
8. Belayev L, Khoutorova L, Atkins K, Cherqui A, Alvarez-Builla J, Bazan NG. LAU-0901, a novel platelet-activating factor receptor antagonist, confers enduring neuroprotection in experimental focal cerebral ischemia in the rat. Brain Res. 2009; 1253: 184-90.
9. Belayev L, Alonso OF, Busto R, Zhao W, Ginsberg MD. Middle cerebral artery occlusion in the rat by intraluminal suture. Neurological and pathological evaluation of an improved model. Stroke. 1996; 27: 1616-22.
10. Ashwal S, Tone B, Tian HR, Chong S, Obenaus A. Comparison of two neonatal ischemic injury models using magnetic resonance imaging. Pediatr Res. 2007; 61: 9-14.
11. Thompson SN, Gibson TR, Thompson BM, Deng Y, Hall ED. Relationship of calpain-mediated proteolysis to the expression of axonal and synaptic plasticity markers following traumatic brain injury in mice. Exp Neurol. 2006; 201: 253-65.
12. Bazan NG, Birkle DL, Reddy TS. Docosahexaenoic acid (22: 6, n-3) is metabolized to lipoxygenase reaction products in the retina. Biochem Biophys Res Commun. 1984; 125: 741-7.
13. Izquierdo I, Fin C, Schmitz PK, Da Silva RC, Jerusalinsky D, Quillfeldt JA, et al. Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance task. Proc Natl Acad Sci U S A. 1995; 92: 5047-51.
14. Kato K, Clark GD, Bazan NG, Zorumski CF. Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation. Nature. 1994; 367: 175-9.
15. Marcheselli VL, Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem. 1996; 271: 24794-9.
16. Bozlu G, Atici A, Turhan AH, Polat A, Nayci A, Okuyaz C, et al. Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury. Brain Res. 2007; 1143: 193-8.
17. Panetta T, Marcheselli VL, Braquet P, Bazan NG. Arachidonic acid metabolism and cerebral blood flow in the normal, ischemic, and reperfused gerbil brain. Inhibition of ischemia-reperfusion-induced cerebral injury by a platelet-activating factor antagonist (BN 52021). Ann N Y Acad Sci. 1989; 559: 340-51.
18. Panetta T, Marcheselli VL, Braquet P, Spinnewyn B, Bazan NG. Effects of a platelet activating factor antagonist (BN 52021) on free fatty acids, diacylglycerols, polyphosphoinositides and blood flow in the gerbil brain: inhibition of ischemia-reperfusion induced cerebral injury. Biochem Biophys Res Commun. 1987; 149: 580-7.
19. Aspey BS, Alp MS, Patel Y, Harrison MJ. Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia-an initial screening study. Metab Brain Dis. 1997; 12: 237-49.
20. Subbanna PK, Tyagi MG. PAF antagonism modifies neuroprotective action of histone deacetylase and calcineurin phosphatase inhibitors in mice. Indian J Exp Biol. 2006; 44: 886-91.
21. Loucks EB, Qayumi AK, Godin DV, English JC, Lim SP, Al Mahmeed T, et al. Therapeutic potential of platelet-activating factor antagonism in the management of myocardial infarction. Can J Cardiol. 2000; 16: 497-504.
22. Iwazaki S, Takeyoshi II, Ohwada S, Sunose Y, Aiba M, Tsutsumi H, et al. FR128998 (a PAF receptor antagonist) counters the increased pulmonary vascular resistance associated with ischemia-reperfusion injury in the canine lung. Int J Angiol. 2001; 10: 10-4.
23. Souza DG, Pinho V, Soares AC, Shimizu T, Ishii S, Teixeira MM. Role of PAF receptors during intestinal ischemia and reperfusion injury. A comparative study between PAF receptor-deficient mice and PAF receptor antagonist treatment. Br J Pharmacol. 2003; 139: 733-40.
24. Grypioti AD, Kostopanagiotou G, Demopoulos CA, Roussos A, Mykoniatis M. Platelet activating factor (PAF) antagonism with ginkgolide B protects the liver against acute injury. Importance of controlling the receptor of PAF. Dig Dis Sci. 2008; 53: 1054-62.
25. Lloberas N, Cruzado JM, Torras J, Herrero-Fresneda I, Riera M, Merlos M, et al. Protective effect of UR-12670 on chronic nephropathy induced by warm ischaemia in ageing uninephrectomized rats. Nephrol Dial Transplant. 2001; 16: 735-41.
26. Esquenazi S, He J, Li N, Bazan NG, Esquenazi I, Bazan HE. A novel platelet activating factor receptor antagonist reduces cell infiltration and expression of inflammatory mediators in mice exposed to desiccating conditions after PRK. Clin Dev Immunol. 2009; 2009: 138513.
27. Musto AE, Samii M. Platelet-activating factor receptor antagonism targets neuroinflammation in experimental epilepsy. Epilepsia. 2011; 52: 551-61.
28. Balami JS, Chen RL, Grunwald IQ, Buchan AM. Neuorological complications of acute ischaemic stroke. Lancet Neurol. 2011; 10: 357-71.
29. Yenari MA, Kauppinen TM, Swanson RA. Microglial activation in stroke: therapeutic targets. Neurotherapeutics. 2010; 7: 378-91.
30. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010; 119: 7-35.
31. Freret T, Schumann-Bard P, Boulouard M, Bouet V. On the importance of long-term functional assessment after stroke to improve translation from bench to bedside. Exp Transl Stroke Med. 2011; 3: 6.
32. Schallert T. Behavioral tests for preclinical intervention assessment. NeuroRx. 2006; 3: 497-504.